Karen Daily, DO - Research

Research at a glance

Top areas of exploration

Breast Neoplasms , 10 publications
Neoplasms , 3 publications
Neoplasm Recurrence, Local , 3 publications
Antineoplastic Combined Chemotherapy Protocols , 3 publications

Research activity

40 publications

407 citations

Why is this important?

Active clinical trials

MK-2870 as a Single Agent and in Combination With MK-3475 Versus TPC (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor鈥�

Investigator: Karen Daily
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2* early breast cancer with intermediate-high or high risk for disease recurrence who completed鈥�

Investigator: Karen Daily
Status: Accepting Candidates
Ages: 18 Years - 130 Years
Sexes: All

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cance

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications鈥�

Investigator: Karen Daily
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

My publications

40 publications

2025

Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast聽Cancer Patients Receiving Adjuvant Therapy.

JACC. CardioOncology

鈥�

2024

Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic.

Clinical and translational science

鈥�

2024

Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms

JCO Precision Oncology

2023

Bilateral primary breast Burkitt's lymphoma in pregnancy.

BMJ case reports

鈥�

2023

Clinical characteristics, prognostic factors, and long-term outcomes associated with epithelial malignancies of the thymus: A 20-year single-institution experience.

Cancer reports (Hoboken, N.J.)

鈥�

BOB体育